RESULTS PRESENTATION 1Q22

















DISCLAIMER

Rio de Janeiro, May 12th, 2022 - **YDUQS Participações S.A.**, one of the largest private organizations in Brazil's higher education private sector, presents its **results for the first quarter of 2022 (1Q22).**

The Company's financial information is presented based on consolidated numbers, in Brazilian Reais, in accordance with the Brazilian Corporation Law and the accounting practices adopted in Brazil (BRGAAP), already in accordance with the International Financial Reporting Standards (IFRS), including IFRS-16.

This document may have forward looking statements that are subject to risks and uncertainties that may lead such expectations to not materialize or substantially differ from expectations. These forecasts express the opinion only for the date they were made, and the Company does not undertake to update them in the light of new information.











AFTER RECOVERY, RESUMPTION OF GROWTH



Intake historical record: +254 thousand students



O GROWTH LEVERS
Digital and Premium with strong expansion

COST OPTIMIZATION
We continue to generate value with improved EBITDA margin



+59% vs 1Q21

On-campus Intake

+3% vs 1Q21

On-campus student base

+28% vs 1Q21 On-campus EBITDA

-2 p.p. vs 1Q21

Reduction of faculty costs/Net Revenue

+44% vs 1Q21

Digital + Premium undergraduate student base

>20% vs 1Q21

Growth of Digital + Premium Net Revenue and EBITDA

+228 seats

Medicine seats already approved in 2022

+29% vs 1Q21

Total of 2,059 DL centers in 1Q22

-3 p.p. vs 1Q21

Reduction of Marketing & Sales expenses/Net Revenue

-3 p.p. vs 1Q21

Reduction of personnel costs/Net Revenue

-0.6 p.p. vs 1Q21

Reduction of leasing (IFRS 16)/Net Revenue

+23% vs 1Q21

Consolidated adjusted EBITDA

+33% vs 1Q21

Adjusted Net Income

R\$ 1.7 billion

Cash and cash equivalents

1.7x

Net Debt/Adjusted EBITDA










EVOLUTION OF THE EDUCATION SECTOR (INEP 2020)



% market share (enrollments and student intake)













INTAKE AND PRICE



Undergraduate intake and price guidance achieved vs 1Q21








+5%

+10%



+30%

+20%

+10%

0%

On-campus

+40%


+50%


> +60%

101 thousand students as

of May/22 (+39% YoY)

+59%





Student Base: 296 thousand (+3% vs 1Q21)

Student Base: 14 thousand (+10% vs 1Q21)

> Net Revenue +28% vs 1Q21 Expectation for Intake 1H22: +15-20% YoY

Medicine: +228 approved seats YTD (~50% intake 1H22) Student base: +14% vs 1Q21

Lower DIS adhesion on the intake pressuring average ticket, which would remain stable if adhesion were the same as 1Q21












-10%

HIGHEST INTAKE IN HISTORY







Digital Process

- Delivery of documents
- Selection
- Payment

44% 36%

Empreenda sem

Ibmec-se.

se prender a teorias.

(Share of interest (1))

Dec-21

National search by IES

Mar-22

Para essa questão do Vestibular, não há dúvida: Medicina é no IDOMED Uma só taxa de inscrição. Uma única prova. Uma ótima oportunidade para estudar em uma das instituições

Iconic campaigns Inscreva-se

DOMED VEST

IDOMED Stácio FAMEAC FAMEJIPA FAPAN UNIFACID



#1 Brand

Estácio - Top 1 on google research

Saiba mais: WYDEN.COM.BR/FMF

+24 p.p.

ahead of the second place

<15 min to complete a registration process

51% of registrations completed entirely on the site










(1) Source: Google Trends Data

MARTHA
FALCÃO Voct aprende mais


WHAT IS NEW IN THE YDUQS DIGITAL ECOSYSTEM





Increasingly engaging, personalized and natively digital teaching and learning experience

- Virtual classroom (Sava)⁽¹⁾ for the entire Estácio undergraduate with students reaching 2x more study time vs previous ⁽²⁾
- App graded 4.6 at play store (3)
- +750 thousand active students in the app monthly (35% access to Sava is though the app) (4)
- +100 students impacted by content built through Design System EnsineMe
 - (+40% access to content through mobile since implementation)



²⁾ Analyzed in test A/B in 2021













Play Store Minha Estácio May.03.22

Data from the week of April.25.22

PREMIUM: CONTINUES WITH STRONG GROWTH









Renewal at 95% Stable vs 1Q21















DIGITAL LEARNING: EXPANSION REMAINS ACCELERATED











Undergraduate average ticket⁽¹⁾ (R\$/month, consolidated digital)

Stable vs 1021

Renewal (2) at 74%














⁽¹⁾ Net revenue adjusted by the effects of laws and court decisions (1Q21) | EBITDA adjusted by non-recurring effects.

ON-CAMPUS: RETURNING TO NORMALITY





+101 thousand students


Intake in 1H22

Growth of +39% vs 1H21

Of which 74 thousand freshmen in health, law and engineering courses (of longer duration)

On-campus students (ex-Medicine) per campus (thousand students)















ON-CAMPUS: STUDENT BASE RESUMES GROWTH







1Q21

On-campus BU +7% vs 4Q21

Semi +50% vs 4Q21 On-campus +3% vs 4Q21 Renewal at 82% -1% vs 1Q21

Undergraduate average ticket(1) (R\$/month, ex-semi on-campus)..... On-campus + Medicine **R\$ 888** 692 650 (+2% vs 1Q21) -6%

1Q22











REVENUE: PREMIUM AND DIGITAL REACHED 53% OF TOTAL









Total Net Revenue by business unit⁽¹⁾ (% of total revenue)














ADJUSTED COSTS AND EXPENSES VS 1Q21 (ex-D&A ex-IFRS)





Bad Debt + Discounts

Bad Debt + Discounts/Net revenue impacted by higher intake, change in DL seasonality with the new quarterly intake, enrollment renewal of medicine students without debt renegotiation. Without these effects, the % would be stable.



M&S expenses

M&S/Net revenue decreases by 3 p.p. vs 1Q21, returning to normality



Costs

Costs/Net revenue -3 p.p.: Reduction of personnel costs, mainly faculty, as a result of operational research



Leasing (IFRS 16)

1Q21

Leasing (IFRS 16)/Net revenue down by -0.6 p.p. vs 1Q21

7.8% -0.6 p.p.

1Q22

Reduction of costs and expenses + discounts/Net Revenue by 5 p.p. vs 1Q21












ADJUSTED EBITDA INCREASES BY 23% IN 1Q22














ADJUSTED NET INCOME INCREASES BY 33% VS 1Q21







R\$ 1.7 billion

Cash and cash equivalents

R\$ 2.4 billion

Net Debt ex-IFRS

1.7x

Net Debt/EBITDA (1)









CASH FLOW AND CAPEX



R\$ million	1Q21	1Q22	Δ%
Adjusted EBITDA ex IFRS 16	240	314	31%
Working capital variation	(28)	(29)	4%
Taxes (IT/SC)	(11)	(9)	-22%
Operating Cash Flow	200	276	38%
Capex	(66)	(86)	30%
Free Cash Flow	134	190	42%
Cash Conversion ⁽²⁾	84%	88%	4 p.p.







CAPEX

(R\$ million)

66

1Q21



1Q22

86

Sustainability & Improvement

Capex 2022 (1)

R\$ 532 million

vs R\$ 544 million in 2021

Digital

and IT

Expansion

Transformation

% of

Total Capex

6%

(30%)



% of net revenue



Buyback Program YTD (3)

5.1 million shares (Up to 20.5 million approved)

R\$ 100.3 million spent on the program













As approved at the OGM of 04.28.2022.

Operating cash flow/Adjusted EBITDA ex-IFRS16

As of 05.11.2022.



1Q22 Results

Student Base (1) +16% vs 1Q21

Digital (1) +25% vs 1Q21 Premium +10% vs 1Q21 On-campus +3% vs 1Q21

Net revenue(2) +10% vs 1Q21

Digital +28% vs 1Q21 Premium +25% vs 1Q21 On-campus -5% vs 1Q21

Adjusted EBITDA(2) +23% vs 1Q21

Digital +25% vs 1Q21 Premium +17% vs 1Q21 On-campus +28% vs 1Q21

EBITDA margin⁽²⁾ 34% (+4 p.p. vs 1Q21)

YDUQS in 2022

7.2-7.4 thousand

Undergraduate medicine student base

3.2-3.4 thousand

Students/campus

2,500

Total DL centers

Capex

R\$532 million

(Long term at 7-8% of Net Revenue)











YDUQS

IR Contact ri@yduqs.com.br www.yduqs.com.br